FDA Wants Another Amgen Study on Lumakras

Amgen will need to run another confirmatory study to win full FDA approval of its lung-cancer drug Lumakras. Amgen says the FDA, which granted conditional approval to the drug in 2021, has turned away its application seeking full approval and called on the company to complete the additional study…#amgen #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news